📊 INGN Key Takeaways
Is INGN a Good Investment? Thesis Analysis
Inogen exhibits deteriorating operational performance with negative operating and net income despite 18.1% revenue growth, indicating margin compression and inability to convert top-line gains into profitability. The company's negative free cash flow of -$13.7M and operating cash burn of -$11.2M raise sustainability concerns, though a strong balance sheet with $103.7M cash and minimal debt provides a financial cushion. Without evidence of profitability recovery, the business appears to be struggling with operational efficiency despite solid gross margins of 44.2%.
Why Buy INGN? Key Strengths
- Strong liquidity position with $103.7M cash and 3.12x current ratio provides financial flexibility
- Healthy gross margin of 44.2% demonstrates pricing power and product viability in medical device sector
- Minimal leverage with 0.00x debt/equity ratio eliminates financial distress risk in near term
- Revenue growth of 18.1% YoY shows market demand for products despite profitability challenges
INGN Investment Risks to Consider
- Negative operating income of -$30.2M and negative net income of -$22.7M signal fundamental profitability issues
- Negative free cash flow of -$13.7M indicates the company is burning cash operationally, unsustainable long-term
- Operating margin of -8.7% suggests severe cost structure problems or pricing pressures relative to revenue scale
- Negative ROE of -11.8% and ROA of -7.6% demonstrate shareholder value destruction despite revenue generation
- Operating cash flow negative despite positive gross profit indicates potential working capital deterioration or high operating costs
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Operating margin improvement and cost structure optimization progress
- Cash burn rate and duration until reserves may face constraints
- Gross margin sustainability and any pricing or cost pressures
- Revenue growth deceleration or acceleration trends in forward quarters
INGN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.12x current ratio provides a solid financial cushion.
INGN Profitability Ratios
INGN vs Default Sector
How Inogen Inc compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INGN Overvalued or Undervalued?
Based on fundamental analysis, Inogen Inc has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INGN Balance Sheet & Liquidity
INGN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Inogen Inc's revenue has declined by 13% over the 5-year period, indicating business contraction. The most recent EPS of $-4.42 indicates the company is currently unprofitable.
INGN Growth Metrics (YoY)
INGN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $74.9M | -$5.3M | $-0.20 |
| Q2 2025 | $74.4M | -$4.2M | $-0.15 |
| Q1 2025 | $63.1M | -$6.2M | $-0.25 |
| Q3 2024 | $68.0M | -$6.0M | $-0.25 |
| Q2 2024 | $68.3M | -$5.6M | $-0.24 |
| Q1 2024 | $55.9M | -$14.6M | $-0.62 |
| Q3 2023 | $68.0M | -$9.5M | $-0.42 |
| Q2 2023 | $68.3M | -$3.4M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INGN Capital Allocation
INGN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Inogen Inc (CIK: 0001294133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INGN
What is the AI rating for INGN?
Inogen Inc (INGN) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INGN's key strengths?
Claude: Strong liquidity position with $103.7M cash and 3.12x current ratio provides financial flexibility. Healthy gross margin of 44.2% demonstrates pricing power and product viability in medical device sector.
What are the risks of investing in INGN?
Claude: Negative operating income of -$30.2M and negative net income of -$22.7M signal fundamental profitability issues. Negative free cash flow of -$13.7M indicates the company is burning cash operationally, unsustainable long-term.
What is INGN's revenue and growth?
Inogen Inc reported revenue of $348.7M.
Does INGN pay dividends?
Inogen Inc does not currently pay dividends.
Where can I find INGN SEC filings?
Official SEC filings for Inogen Inc (CIK: 0001294133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INGN's EPS?
Inogen Inc has a diluted EPS of $-0.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INGN a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Inogen Inc has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INGN stock overvalued or undervalued?
Valuation metrics for INGN: ROE of -11.8% (sector avg: 15%), net margin of -6.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INGN stock in 2026?
Our dual AI analysis gives Inogen Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INGN's free cash flow?
Inogen Inc's operating cash flow is $-11.2M, with capital expenditures of $2.5M. FCF margin is -3.9%.
How does INGN compare to other Default stocks?
Vs Default sector averages: Net margin -6.5% (avg: 12%), ROE -11.8% (avg: 15%), current ratio 3.12 (avg: 1.8).